FDA limiting use of monoclonal antibodies for COVID-19 due to Omicron variant

On January 24, 2022, the FDA limits the use of certain Monoclonal Antibodies to treat COVID-19 due to the Omicron Variant, even though we know doctors have been saving lives using Monoclonal Antibodies.. [1, 2]

“Two monoclonal antibody treatments – bamlanivimab and etesevimab (administered together) and REGEN-COV (casirivimab and imdevimab) – to limit their use to only when the patient is likely to have been infected with or exposed to a variant that is susceptible to these treatments” the FDA state “data show these treatments are highly unlikely to be active against the omicron variant, which is circulating at a very high frequency throughout the United States.”

This FDA announcement happened 3 days after the controversial drug remdesivir was granted outpatient approval by the FDA!